Ibrutinib maintenance after frontline treatment in patients with mantle cell lymphoma.

Autor: Karmali R; Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL.; Robert H. Lurie Comprehensive Cancer Center, Chicago, IL., Abramson JS; Massachusetts General Hospital Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA., Stephens DM; Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT., Barnes J; Massachusetts General Hospital Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA., Winter JN; Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL.; Robert H. Lurie Comprehensive Cancer Center, Chicago, IL., Ma S; Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL.; Robert H. Lurie Comprehensive Cancer Center, Chicago, IL., Gao J; Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL., Kaplan J; Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL., Petrich AM; AbbVie, North Chicago, IL., Hochberg E; Massachusetts General Hospital Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA., Takvorian T; Massachusetts General Hospital Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA., Mi X; Department of Preventive Medicine-Biostatistics, Northwestern University, Chicago, IL., Nelson V; Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL., Gordon LI; Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL.; Robert H. Lurie Comprehensive Cancer Center, Chicago, IL., Pro B; Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL.; Robert H. Lurie Comprehensive Cancer Center, Chicago, IL.

Publikováno v: Blood advances [Blood Adv] 2023 Dec 12; Vol. 7 (23), pp. 7361-7368.

Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial.

Autor: Soumerai JD; Massachusetts General Hospital Cancer Center, Boston, MA, USA., Mato AR; Memorial-Sloan Kettering Cancer Center, New York, NY, USA., Dogan A; Memorial-Sloan Kettering Cancer Center, New York, NY, USA., Seshan VE; Memorial-Sloan Kettering Cancer Center, New York, NY, USA., Joffe E; Memorial-Sloan Kettering Cancer Center, New York, NY, USA., Flaherty K; Memorial-Sloan Kettering Cancer Center, New York, NY, USA., Carter J; Memorial-Sloan Kettering Cancer Center, New York, NY, USA., Hochberg E; Massachusetts General Hospital Cancer Center, Boston, MA, USA., Barnes JA; Massachusetts General Hospital Cancer Center, Boston, MA, USA., Hamilton AM; Memorial-Sloan Kettering Cancer Center, New York, NY, USA., Abramson JS; Massachusetts General Hospital Cancer Center, Boston, MA, USA., Batlevi CL; Memorial-Sloan Kettering Cancer Center, New York, NY, USA., Matasar MJ; Memorial-Sloan Kettering Cancer Center, New York, NY, USA., Noy A; Memorial-Sloan Kettering Cancer Center, New York, NY, USA., Owens CN; Memorial-Sloan Kettering Cancer Center, New York, NY, USA., Palomba ML; Memorial-Sloan Kettering Cancer Center, New York, NY, USA., Kumar A; Memorial-Sloan Kettering Cancer Center, New York, NY, USA., Takvorian T; Massachusetts General Hospital Cancer Center, Boston, MA, USA., Ni A; Memorial-Sloan Kettering Cancer Center, New York, NY, USA., Choma M; Memorial-Sloan Kettering Cancer Center, New York, NY, USA., Friedman C; Memorial-Sloan Kettering Cancer Center, New York, NY, USA., Chadha P; Memorial-Sloan Kettering Cancer Center, New York, NY, USA., Simkins E; Massachusetts General Hospital Cancer Center, Boston, MA, USA., Ruiters J; Massachusetts General Hospital Cancer Center, Boston, MA, USA., Sechio S; Massachusetts General Hospital Cancer Center, Boston, MA, USA., Portman D; Massachusetts General Hospital Cancer Center, Boston, MA, USA., Ramos L; Massachusetts General Hospital Cancer Center, Boston, MA, USA., Nolet N; Massachusetts General Hospital Cancer Center, Boston, MA, USA., Mahajan N; Memorial-Sloan Kettering Cancer Center, New York, NY, USA., Martignetti R; Massachusetts General Hospital Cancer Center, Boston, MA, USA., Mi J; Memorial-Sloan Kettering Cancer Center, New York, NY, USA., Scorsune K; Massachusetts General Hospital Cancer Center, Boston, MA, USA., Lynch J; Massachusetts General Hospital Cancer Center, Boston, MA, USA., McGree B; Massachusetts General Hospital Cancer Center, Boston, MA, USA., Hughes S; Memorial-Sloan Kettering Cancer Center, New York, NY, USA., Grieve C; Memorial-Sloan Kettering Cancer Center, New York, NY, USA., Roeker LE; Memorial-Sloan Kettering Cancer Center, New York, NY, USA., Thompson M; Memorial-Sloan Kettering Cancer Center, New York, NY, USA., Johnson PC; Massachusetts General Hospital Cancer Center, Boston, MA, USA., Roshal M; Memorial-Sloan Kettering Cancer Center, New York, NY, USA., Huang J; Beigene, San Mateo, CA, USA., Biondo J; Genentech, San Francisco, CA, USA., Wu Q; Genentech, San Francisco, CA, USA., Jacob A; Adaptive Biotechnologies, Seattle, WA, USA., Abdel-Wahab O; Memorial-Sloan Kettering Cancer Center, New York, NY, USA., Zelenetz AD; Memorial-Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: zeleneta@mskcc.org.

Publikováno v: The Lancet. Haematology [Lancet Haematol] 2021 Dec; Vol. 8 (12), pp. e879-e890.

Panobinostat in combination with rituximab in heavily pretreated diffuse large B-cell lymphoma: Results of a phase II study.

Autor: Barnes JA; Massachusetts General Hospital Cancer Center, Dana-Farber Cancer Institute, Boston, MA, USA., Redd R; Dana-Farber Cancer Institute, Boston, MA, USA., Fisher DC; Dana-Farber Cancer Institute, Boston, MA, USA., Hochberg EP; Massachusetts General Hospital Cancer Center, Dana-Farber Cancer Institute, Boston, MA, USA., Takvorian T; Massachusetts General Hospital Cancer Center, Dana-Farber Cancer Institute, Boston, MA, USA., Neuberg D; Dana-Farber Cancer Institute, Boston, MA, USA., Jacobsen E; Dana-Farber Cancer Institute, Boston, MA, USA., Abramson JS; Massachusetts General Hospital Cancer Center, Dana-Farber Cancer Institute, Boston, MA, USA.

Publikováno v: Hematological oncology [Hematol Oncol] 2018 Oct; Vol. 36 (4), pp. 633-637. Date of Electronic Publication: 2018 Jun 28.

Advances in Hodgkin Lymphoma Treatment: From Molecular Biology to Clinical Practice.

Autor: Benevolo Savelli, Corrado¹ (AUTHOR) cbenevolosavelli@cittadellasalute.to.it, Bisio, Matteo¹ (AUTHOR), Legato, Luca¹ (AUTHOR), Fasano, Filippo¹ (AUTHOR), Santambrogio, Elisa¹ (AUTHOR), Nicolosi, Maura¹ (AUTHOR), Morra, Deborah¹ (AUTHOR), Boccomini, Carola¹ (AUTHOR), Freilone, Roberto¹ (AUTHOR), Botto, Barbara¹ (AUTHOR), Novo, Mattia¹ (AUTHOR) cbenevolosavelli@cittadellasalute.to.it

Publikováno v: Cancers. May2024, Vol. 16 Issue 10, p1830. 26p.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.